ArticlePloS one2013
Epidemiology of candidemia in Latin America: a laboratory-based survey.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it, 369 citations in OpenAlex.
- Antifungal pharmacodynamics: Latin America's perspective.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesPooled it
- First Isolation ofJournal of fungi (Basel, Switzerland) · 2026Article
- Shift in Candidemia Epidemiology and Emerging Fluconazole Resistance inJournal of fungi (Basel, Switzerland) · 2026Article
- Clinical Characteristics, Management, and 30-Day Mortality Predictors in an 18-Year Pediatric Candidemia Cohort.Journal of fungi (Basel, Switzerland) · 2026Article
- Ten-Year Trends in Candidemia at a Tertiary-Care Hospital in Spain (2015-2024): Epidemiological Shifts, Diagnostic Acceleration, and Impact of Antifungal Stewardship in the COVID-19 and Post-Pandemic Era.Journal of fungi (Basel, Switzerland) · 2026Article
- Neonatal Candidemia in Latin America: Trends, Resistance, and Prevention Strategies (2008-2025).Journal of fungi (Basel, Switzerland) · 2026Review
- Article
- Optimizing Antifungal Use Through Interdisciplinary Intervention in the Hematology Unit.Journal of fungi (Basel, Switzerland) · 2026Article
- Candidemia in a tertiary hospital in Southern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Article
- Genomic epidemiology of Colombian resistantAntimicrobial agents and chemotherapy · 2025Article
- Shifting Paradigms in Antifungal Prophylaxis and Their Effects on Candidemia Outcomes in Hematological Malignancies: A 14-Year Experience from a Single Tertiary Center.Journal of fungi (Basel, Switzerland) · 2025Article
- Changing Climate, ChangingJournal of fungi (Basel, Switzerland) · 2025Review
- Invasive Candidiasis in Contexts of Armed Conflict, High Violence, and Forced Displacement in Latin America and the Caribbean (2005-2025).Journal of fungi (Basel, Switzerland) · 2025Review
- Heterogeneity ofMicrobiology spectrum · 2025Article
- Virulence Factors and Molecular Identification ofJournal of fungi (Basel, Switzerland) · 2025Article
- Epidemiological characteristics of pediatric patients with invasive candidiasis in an intensive care unit in southwestern ColombiaBiomedica : revista del Instituto Nacional de Salud · 2025Observational
- An 11-Year retrospective analysis of candidiasis epidemiology, risk factors, and antifungal susceptibility in a tertiary care hospital in China.Scientific reports · 2025Article
- Candidemia in ICU Patients: What Are the Real Game-Changers for Survival?Journal of fungi (Basel, Switzerland) · 2025Article
- Clinical and molecular features of candidemia: a three-year retrospective study in Northern Guizhou, China.Frontiers in cellular and infection microbiology · 2025Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 12 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe epidemiology of candidemia varies depending on the geographic region. Little is known about the epidemiology of candidemia in Latin America.
methodsWe conducted a 24-month laboratory-based survey of candidemia in 20 centers of seven Latin American countries. Incidence rates were calculated and the epidemiology of candidemia was characterized.
resultsAmong 672 episodes of candidemia, 297 (44.2%) occurred in children (23.7% younger than 1 year), 36.2% in adults between 19 and 60 years old and 19.6% in elderly patients. The overall incidence was 1.18 cases per 1,000 admissions, and varied across countries, with the highest incidence in Colombia and the lowest in Chile. Candida albicans (37.6%), C. parapsilosis (26.5%) and C. tropicalis (17.6%) were the leading agents, with great variability in species distribution in the different countries. Most isolates were highly susceptible to fluconazole, voriconazole, amphotericin B and anidulafungin. Fluconazole was the most frequent agent used as primary treatment (65.8%), and the overall 30-day survival was 59.3%.
conclusionsThis first large epidemiologic study of candidemia in Latin America showed a high incidence of candidemia, high percentage of children, typical species distribution, with C. albicans, C. parapsilosis and C. tropicalis accounting for the majority of episodes, and low resistance rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.